.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BA03_Fulvestrant.Fulvestrant .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BA03_Fulvestrant.Fulvestrant| name: | Fulvestrant | |
| ATC code: | L02BA03 | route: | intramuscular |
| compartments: | 2 | |
| dosage: | 500 | mg |
| volume of distribution: | 3.0 | L |
| clearance: | 11.4 | L/h |
| other parameters in model implementation | ||
Fulvestrant is a selective estrogen receptor degrader (SERD) used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. It binds to estrogen receptors and accelerates their degradation, thereby inhibiting estrogen signaling. Fulvestrant is approved and used in current clinical practice.
Pharmacokinetic parameters reported for adult female breast cancer patients. Model parameters are based on studies of repeated IM injection with clinical standard dosage.